X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cipla with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ADCOCK INGRAM (S. Africa) - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   ADCOCK INGRAM
EQUITY SHARE DATA
    CIPLA
Mar-17
ADCOCK INGRAM
Jun-14
CIPLA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs622371-   
Low Rs458268-   
Sales per share (Unadj.) Rs181.9110.4-  
Earnings per share (Unadj.) Rs12.9-27.8-  
Cash flow per share (Unadj.) Rs29.3-23.1-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs155.786.7-  
Shares outstanding (eoy) m804.51168.78-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.02.9 102.6%   
Avg P/E ratio x42.0-11.5 -365.5%  
P/CF ratio (eoy) x18.4-13.9 -133.0%  
Price / Book Value ratio x3.53.7 94.1%  
Dividend payout %15.50-   
Avg Mkt Cap Rs m434,51653,923 805.8%   
No. of employees `00023.04.3 536.8%   
Total wages/salary Rs m26,3383,384 778.2%   
Avg. sales/employee Rs Th6,349.14,341.2 146.3%   
Avg. wages/employee Rs Th1,143.0788.3 145.0%   
Avg. net profit/employee Rs Th449.3-1,093.9 -41.1%   
INCOME DATA
Net Sales Rs m146,30218,637 785.0%  
Other income Rs m2,287131 1,752.3%   
Total revenues Rs m148,58918,767 791.7%   
Gross profit Rs m24,758-3,230 -766.6%  
Depreciation Rs m13,229804 1,644.7%   
Interest Rs m1,594505 315.7%   
Profit before tax Rs m12,222-4,408 -277.2%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,798275 652.6%   
Profit after tax Rs m10,354-4,696 -220.5%  
Gross profit margin %16.9-17.3 -97.7%  
Effective tax rate %14.7-6.2 -235.4%   
Net profit margin %7.1-25.2 -28.1%  
BALANCE SHEET DATA
Current assets Rs m87,37013,650 640.1%   
Current liabilities Rs m33,0817,680 430.7%   
Net working cap to sales %37.132.0 115.8%  
Current ratio x2.61.8 148.6%  
Inventory Days Days87111 78.4%  
Debtors Days Days62124 50.3%  
Net fixed assets Rs m111,5677,956 1,402.2%   
Share capital Rs m1,60987 1,859.5%   
"Free" reserves Rs m123,6450-   
Net worth Rs m125,25414,628 856.3%   
Long term debt Rs m36,4545,140 709.1%   
Total assets Rs m209,53227,633 758.3%  
Interest coverage x8.7-7.7 -112.1%   
Debt to equity ratio x0.30.4 82.8%  
Sales to assets ratio x0.70.7 103.5%   
Return on assets %5.7-15.2 -37.6%  
Return on equity %8.3-32.1 -25.7%  
Return on capital %8.5-19.8 -42.9%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Net fx Rs m33,3880-   
CASH FLOW
From Operations Rs m23,8241,591 1,497.6%  
From Investments Rs m-13,127-488 2,687.4%  
From Financial Activity Rs m-13,2394,665 -283.8%  
Net Cashflow Rs m-2,4785,768 -43.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.12 Rs / ZAR

Compare CIPLA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare CIPLA With: MERCK LTD  ALEMBIC PHARMA  VENUS REMEDIES  DISHMAN PHARMA  IPCA LABS  



Today's Market

Of IPOs, LIC-IDBI Bank Deal, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed marginally higher on Friday last week. All sectoral indices traded in green, with stocks in the IT sector and stocks in the pharma sector, leading the gains.

Related Views On News

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8% (Quarterly Result Update)

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Sintex's Auditor Resigns. How You Can Protect Yourself from Such Stocks(The 5 Minute Wrapup)

Jul 20, 2018

While the attack on the bad corporate governance is an overhang in the near term...this can be a game-changer in the years to come.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

PPF v/s Mutual Funds: Which Is Better?(Outside View)

Jul 10, 2018

PersonalFN highlights the key points of distinction between PPF and mutual funds.

ICICI Pru Mutual Fund Tarakki Karega! - The Unethical Way?(Outside View)

Jul 11, 2018

PersonalFN explains how ICICI Prudential Mutual Fund flouted the norms of related party transactions while subscribing to the IPO of ICICI Securities.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jul 23, 2018 09:29 AM

TRACK CIPLA

CIPLA - FDC LTD. COMPARISON

COMPARE CIPLA WITH

MARKET STATS